LakeShore Biopharma Co., Ltd.
LakeShore Biopharma Co., Ltd. (LSBPW) Stock Overview
Explore LakeShore Biopharma Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
381.1K
P/E Ratio
-0.49
EPS (TTM)
N/A
ROE
-0.49%
LSBPW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of LakeShore Biopharma Co., Ltd. (LSBPW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 42.00, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.04.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.49 and a market capitalization of 381.1K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
LakeShore Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Wang Xu
758
Building No. 2, Beijing
1970